Synopsis
Synopsis
0
CEP/COS
0
VMF
0
South Africa
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 4-t-butyl-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide
2. Bosentan Anhydrous
3. Bosentan Monohydrate
4. Ro 47 0203
5. Ro 47-0203
6. Ro 470203
7. Ro-47-0203
8. Tracleer
1. 147536-97-8
2. Tracleer
3. Actelion
4. Bosentan Anhydrous
5. Ro 47-0203
6. Ro-47-0203
7. Anhydrous Bosentan
8. Bosentan [usan:inn:ban]
9. 4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide
10. P-tert-butyl-n-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide
11. Bosentan (inn)
12. 4-(tert-butyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-[2,2'-bipyrimidin]-4-yl)benzenesulfonamide
13. Chembl957
14. Xul93r30k2
15. N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-yl-pyrimidin-4-yl]-4-tert-butyl-benzenesulfonamide
16. Chebi:51450
17. 147536-97-8 (free)
18. 174227-18-0
19. Benzenesulfonamide, 4-(1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)(2,2'-bipyrimidin)-4-yl)-
20. Ncgc00167440-01
21. Bosentan [inn]
22. Dsstox_cid_26627
23. Dsstox_rid_81776
24. Dsstox_gsid_46627
25. 1174918-31-0
26. 4-(1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) Benzenesulfornamide
27. 4-tert-butyl-n-[6-(2-hydroxyethyloxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-yl-pyrimidin-4-yl]benzenesulfonamide
28. Benzenesulfonamide, 4-(1,1-dimethylethyl)-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]-
29. Bosentanum
30. Ro-47-0203/029
31. 4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulfonamide
32. Cas-147536-97-8
33. Ro 47-0203/039
34. Sr-05000001532
35. Ro-470203029
36. Ro-47-0203-029
37. Unii-xul93r30k2
38. 4-tert-butyl-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide
39. 4-(1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamide
40. Ks-5062
41. Starbld0043886
42. Bosentan [mi]
43. Ro-47-0203/039
44. Bosentan [who-dd]
45. Schembl4218
46. Gtpl3494
47. Dtxsid7046627
48. Hms2090n14
49. Hms3652f15
50. Hms3715n05
51. Hms3750a13
52. Bcp05202
53. Hy-a0013
54. Zinc1538857
55. Tox21_112444
56. Ac-148
57. Bdbm50061101
58. Pdsp1_001731
59. Pdsp2_001714
60. S4220
61. Akos015852063
62. Tox21_112444_1
63. Am84442
64. Bcp9000445
65. Ccg-221182
66. Cs-0381
67. Db00559
68. Sb17356
69. Ncgc00167440-02
70. Bb164259
71. B5118
72. Ft-0658809
73. Sw199648-3
74. D07538
75. W18800
76. Ab01275536-01
77. 212b550
78. A808658
79. L001086
80. Q419769
81. J-008366
82. Sr-05000001532-1
83. Sr-05000001532-2
84. Sr-05000001532-4
85. Z1541632805
86. 4-(1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2''-bipyrimidin)-4-yl) Benzenesulfornamide
87. 4-(1,1-dimethylethyl)-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]benzenesulfonamide
88. 4-(tert-butyl)-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]benzenesulfonamide
89. 4-tert Butyl-n-[4-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)pyrimidin-6-yl]benzenesulphonamide
90. 4-tert-butyl-n-[6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-benzenesulfonamide
91. 4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-[2,2'-bipyrimidine]-4-yl]benzene-1-sulfonamide
92. 4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2''-bipyrimidin-4-yl]benzenesulfonamide
93. 4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]benzenesulfonamide
94. 4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzene-1-sulfonamide
95. 4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzenesulfonamide
96. K86
Molecular Weight | 551.6 g/mol |
---|---|
Molecular Formula | C27H29N5O6S |
XLogP3 | 3.8 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 11 |
Rotatable Bond Count | 11 |
Exact Mass | 551.18385484 g/mol |
Monoisotopic Mass | 551.18385484 g/mol |
Topological Polar Surface Area | 154 Ų |
Heavy Atom Count | 39 |
Formal Charge | 0 |
Complexity | 839 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Tracleer |
PubMed Health | Bosentan (By mouth) |
Drug Classes | Antihypertensive |
Drug Label | Tracleer is the proprietary name for bosentan, an endothelin receptor antagonist that belongs to a class of highly substituted pyrimidine derivatives, with no chiral centers. It is designated chemically as 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-me... |
Active Ingredient | Bosentan |
Dosage Form | Tablet |
Route | Oral |
Strength | 125mg; 62.5mg |
Market Status | Prescription |
Company | Actelion Pharms |
2 of 2 | |
---|---|
Drug Name | Tracleer |
PubMed Health | Bosentan (By mouth) |
Drug Classes | Antihypertensive |
Drug Label | Tracleer is the proprietary name for bosentan, an endothelin receptor antagonist that belongs to a class of highly substituted pyrimidine derivatives, with no chiral centers. It is designated chemically as 4-tert-butyl-N-[6-(2-hydroxy-ethoxy)-5-(2-me... |
Active Ingredient | Bosentan |
Dosage Form | Tablet |
Route | Oral |
Strength | 125mg; 62.5mg |
Market Status | Prescription |
Company | Actelion Pharms |
Used in the treatment of pulmonary arterial hypertension (PAH), to improve exercise ability and to decrease the rate of clinical worsening (in patients with WHO Class III or IV symptoms).
FDA Label
Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III. Efficacy has been shown in:
- Primary (idiopathic and familial) PAH;
- PAH secondary to scleroderma without significant interstitial pulmonary disease;
- PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology.
Some improvements have also been shown in patients with PAH WHO functional class II.
Tracleer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.
Bosentan belongs to a class of drugs known as endothelin receptor antagonists (ERAs). Patients with PAH have elevated levels of endothelin, a potent blood vessel constrictor, in their plasma and lung tissue. Bosentan blocks the binding of endothelin to its receptors, thereby negating endothelin's deleterious effects.
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Endothelin Receptor Antagonists
Compounds and drugs that bind to and inhibit or block the activation of ENDOTHELIN RECECPTORS. (See all compounds classified as Endothelin Receptor Antagonists.)
C02KX01
C02KX01
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
C - Cardiovascular system
C02 - Antihypertensives
C02K - Other antihypertensives
C02KX - Antihypertensives for pulmonary arterial hypertension
C02KX01 - Bosentan
Absorption
Absolute bioavailability is approximately 50% and food does not affect absorption.
Route of Elimination
Bosentan is eliminated by biliary excretion following metabolism in the liver.
Volume of Distribution
18 L
Clearance
4 L/h [patients with pulmonary arterial hypertension]
Bosentan is metabolized in the liver by the cytochrome P450 enzymes CYP2C9 and CYP3A4 (and possibly CYP2C19), producing three metabolites, one of which, Ro 48-5033, is pharmacologically active and may contribute 10 to 20% to the total activity of the parent compound.
Bosentan has known human metabolites that include 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-hydroxyphenoxy)-[2,2-]bipyrimidinyl-4-yl]-benzenesulfonamide and Hydroxy Bosentan.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
Terminal elimination half-life is about 5 hours in healthy adult subjects.
Endothelin-1 (ET-1) is a neurohormone, the effects of which are mediated by binding to ETA and ETB receptors in the endothelium and vascular smooth muscle. It displays a slightly higher affinity towards ETA receptors than ETB receptors. ET-1 concentrations are elevated in plasma and lung tissue of patients with pulmonary arterial hypertension, suggesting a pathogenic role for ET-1 in this disease. Bosentan is a specific and competitive antagonist at endothelin receptor types ETA and ETB.
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Tracleer-Generic (bosentan) is an endothelin receptor antagonist small molecule drug candidate, which is indicated for the treatment of pulmonary arterial hypertension.
Lead Product(s): Bosentan Hydrate
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Tracleer-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Natco Pharma
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 10, 2025
Lead Product(s) : Bosentan Hydrate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Natco Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin & Natco Pharma Gets Final Approval for its ANDA for Bosentan Tablets
Details : Tracleer-Generic (bosentan) is an endothelin receptor antagonist small molecule drug candidate, which is indicated for the treatment of pulmonary arterial hypertension.
Product Name : Tracleer-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 10, 2025
Details:
Bosentan is a specific and competitive antagonist at endothelin receptor types ETA and ETB. It is developed for for the treatment of PAH in pediatric patients aged 3 years and older with idiopathic or congenial PAH to improve pulmonary vascular resistance.
Lead Product(s): Bosentan Hydrate
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Bosentan-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 15, 2023
Lead Product(s) : Bosentan Hydrate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Receives Tentative Approval from The USFDA for Bosentan Tablets for Oral Suspension
Details : Bosentan is a specific and competitive antagonist at endothelin receptor types ETA and ETB. It is developed for for the treatment of PAH in pediatric patients aged 3 years and older with idiopathic or congenial PAH to improve pulmonary vascular resistanc...
Product Name : Bosentan-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2023
4- (1,1-dimethylethyl)-N-[6-chloro-5- (2-methoxyph...
CAS Number : 150727-06-3
End Use API : Bosentan Hydrate
About The Company : Established in 1975, Acharya Group is a trusted and well-established chemical manufacturing company renowned for its commitment to technological excellence. Ach...
tert-Butyl benzene sulfonamide
CAS Number : 6292-59-7
End Use API : Bosentan Hydrate
About The Company : The Bakul Group of companies headquartered in Mumbai, India are engaged in the development and manufacture of high-quality Active Pharmaceutical Ingredients (AP...
Diethyl (O-Methoxy Phenoxy) Malonate
CAS Number : 150726-89-9
End Use API : Bosentan Hydrate
About The Company : Ramdev Chemicals Pvt. Ltd. is one of the fastest growing Active Pharmaceuticl Drugs, Drug Intermediates, Storage Fine Chemical Company in India which have speci...
CAS Number : 138588-40-6
End Use API : Bosentan Hydrate
About The Company : Ramdev Chemicals Pvt. Ltd. is one of the fastest growing Active Pharmaceuticl Drugs, Drug Intermediates, Storage Fine Chemical Company in India which have speci...
2-Amidinopyrimidine hydrochloride
CAS Number : 138588-40-6
End Use API : Bosentan Hydrate
About The Company : Sandoo Pharmaceuticals and Chemcials Co.,Ltd was established in 2009, with a young and active team, located in Ningbo, China. Specializes in exporting and imp...
Regulatory Info :
Registration Country : Sweden
Brand Name : bosentan Actavis
Dosage Form : FILM COATED PILL
Dosage Strength : 125 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Australia
Brand Name : Bosentan Mylan
Dosage Form : tablet
Dosage Strength : 62.5 mg
Packaging : 60
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Bosentan Mylan
Dosage Form : tablet
Dosage Strength : 125 mg
Packaging : 60
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Bosentan Mylan
Dosage Form : tablet
Dosage Strength : 62.5 mg
Packaging : 60
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Italy
Brand Name : BOSENTAN AUROBINDO
Dosage Form : Film-Coated Tablets
Dosage Strength : 62.5 mg
Packaging : 56 UNITS 62.5 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 62.5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info :
Registration Country : Norway
Brand Name : Bosentan Sandoz
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 62.5 mg
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Italy
Brand Name : BOSENTAN SUN
Dosage Form : Film-Coated Tablets
Dosage Strength : 125 mg
Packaging : 56 UNITS 125 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info : Prescription
Registration Country : Canada
BOSENTAN (BOSENTAN MONOHYDRATE)
Brand Name : TARO-BOSENTAN
Dosage Form : TABLET
Dosage Strength : 125MG
Packaging :
Approval Date :
Application Number : 2483149
Regulatory Info : Prescription
Registration Country : Canada
Regulatory Info : RX
Registration Country : USA
Brand Name : BOSENTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 125MG
Packaging :
Approval Date : 2019-04-26
Application Number : 207760
Regulatory Info : RX
Registration Country : USA
RLD : No
TE Code :
Brand Name : BOSENTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 62.5MG
Approval Date : 2019-04-26
Application Number : 206002
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Brand Name : BOSENTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 62.5MG
Approval Date : 2019-04-26
Application Number : 205699
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Brand Name : BOSENTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 125MG
Approval Date : 2019-04-26
Application Number : 205699
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Brand Name : BOSENTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 62.5MG
Approval Date : 2019-04-26
Application Number : 208695
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Brand Name : BOSENTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 125MG
Approval Date : 2019-04-26
Application Number : 208695
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : Yes
TE Code : AB
Brand Name : TRACLEER
Dosage Form : TABLET, FOR SUSPENSION;ORAL
Dosage Strength : 32MG
Approval Date : 2017-09-05
Application Number : 209279
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB
RLD : No
TE Code :
Brand Name : BOSENTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 62.5MG
Approval Date : 2020-01-15
Application Number : 205173
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Brand Name : BOSENTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 125MG
Approval Date : 2020-01-15
Application Number : 205173
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AB
Brand Name : BOSENTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 62.5MG
Approval Date : 2019-04-26
Application Number : 207760
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : BOSENTAN
Dosage Form : TABLET;ORAL
Dosage Strength : 125MG
Approval Date : 2019-04-26
Application Number : 207760
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
Regulatory Info :
Registration Country : Italy
Brand Name : BOSENTAN ABDI
Dosage Form : Film-Coated Tablets
Dosage Strength : 125 mg
Packaging : 56 UNITS 125 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : BOSENTAN ABDI
Dosage Form : Film-Coated Tablets
Dosage Strength : 62.5 mg
Packaging : 56 UNITS 62.5 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Norway
Brand Name : Bosentan Accord
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 125 mg
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Sweden
Brand Name : bosentan Actavis
Dosage Form : FILM COATED PILL
Dosage Strength : 62.5 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Italy
Brand Name : TRACLEER
Dosage Form : Coated Tablets
Dosage Strength : 62.5 mg
Packaging : 56 UNITS 62.5 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Switzerland
Brand Name : Tracleer
Dosage Form : Filmtable
Dosage Strength : 62.5mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Sweden
Brand Name : Tracleer
Dosage Form : FILM COATED PILL
Dosage Strength : 62.5 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Italy
Brand Name : Tracleer
Dosage Form : Bosentan 32Mg 56 Combined Oral Use
Dosage Strength : 56 cpr dispers 32 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Switzerland
Brand Name : Bosentan-Mepha
Dosage Form : Film-Coated Tablets
Dosage Strength : 125mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Italy
Brand Name : BOSENTAN TEVA
Dosage Form : Film-Coated Tablets
Dosage Strength : 62.5 mg
Packaging : 56 UNITS 62.5 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Australia
Brand Name : Bosentan Mylan
Dosage Form : tablet
Dosage Strength : 62.5 mg
Packaging : 60
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Bosentan Mylan
Dosage Form : tablet
Dosage Strength : 125 mg
Packaging : 60
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Bosentan APO
Dosage Form : tablet
Dosage Strength : 62.5 mg
Packaging : 60
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Bosentan APO
Dosage Form : tablet
Dosage Strength : 62.5 mg
Packaging : 60
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Bosentan GH
Dosage Form : tablet
Dosage Strength : 125 mg
Packaging : 60
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Bosentan GH
Dosage Form : tablet
Dosage Strength : 125 mg
Packaging : 60
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Bosentan RBX
Dosage Form : tablet
Dosage Strength : 62.5 mg
Packaging : 60
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Bosentan RBX
Dosage Form : tablet
Dosage Strength : 62.5 mg
Packaging : 60
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Bosentan RBX
Dosage Form : tablet
Dosage Strength : 62.5 mg
Packaging : 60
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : BOSENTAN DR.REDDY'S
Dosage Form : tablet
Dosage Strength : 62.5 mg
Packaging : 60
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info : Generic
Registration Country : Turkey
Brand Name :
Dosage Form : Tablet
Dosage Strength : 62.5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : Turkey
Packaging :
Regulatory Info : Generic
Dosage : Tablet
Dosage Strength : 62.5MG
Brand Name :
Approval Date :
Application Number :
Registration Country : Turkey
Regulatory Info : Generic
Registration Country : India
Brand Name :
Dosage Form : TABLET
Dosage Strength : 125MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : India
Packaging :
Regulatory Info : Generic
Dosage : TABLET
Dosage Strength : 125MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 125MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Film Coated Tablet
Dosage Strength : 125MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : Argentina
Brand Name : Endotan
Dosage Form : Tablet
Dosage Strength : 62.5MG
Packaging : 30/60 Tabs
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Argentina
Packaging : 30/60 Tabs
Regulatory Info :
Dosage : Tablet
Dosage Strength : 62.5MG
Brand Name : Endotan
Approval Date :
Application Number :
Registration Country : Argentina
Regulatory Info :
Registration Country : Russia
Brand Name : Bozenex
Dosage Form : Film-Coated Tablet
Dosage Strength : 62.5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Russia
Packaging :
Regulatory Info :
Dosage : Film-Coated Tablet
Dosage Strength : 62.5MG
Brand Name : Bozenex
Approval Date :
Application Number :
Registration Country : Russia
Regulatory Info :
Registration Country : Turkey
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 62.5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Turkey
Packaging :
Regulatory Info :
Dosage : Film Coated Tablet
Dosage Strength : 62.5MG
Brand Name :
Approval Date :
Application Number :
Registration Country : Turkey
Regulatory Info :
Registration Country : Turkey
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 125MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Turkey
Packaging :
Regulatory Info :
Dosage : Film Coated Tablet
Dosage Strength : 125MG
Brand Name :
Approval Date :
Application Number :
Registration Country : Turkey
Regulatory Info : Generic
Registration Country : India
Brand Name :
Dosage Form : Tablet
Dosage Strength :
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : India
Packaging :
Regulatory Info : Generic
Dosage : Tablet
Dosage Strength :
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : Turkey
Brand Name : SENTARIN
Dosage Form : TABLETS
Dosage Strength : 62.5MG
Packaging : 56 TABLETS
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Turkey
Packaging : 56 TABLETS
Regulatory Info :
Dosage : TABLETS
Dosage Strength : 62.5MG
Brand Name : SENTARIN
Approval Date :
Application Number :
Registration Country : Turkey
Regulatory Info :
Registration Country : Turkey
Brand Name : SENTARIN
Dosage Form : TABLETS
Dosage Strength : 125MG
Packaging : 56 TABLETS
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Turkey
Packaging : 56 TABLETS
Regulatory Info :
Dosage : TABLETS
Dosage Strength : 125MG
Brand Name : SENTARIN
Approval Date :
Application Number :
Registration Country : Turkey
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Dosage Form : Cream / Lotion / Ointment
Grade : Topical
Application : Topical
Excipient Details : L-Phenylalanine is used as an excipient in a variety of topical dosage forms such as cream, lotion, gel, etc.
Pharmacopoeia Ref : NA
Technical Specs : Molecular weight: 165.19 g/mol
Ingredient(s) : L-Phenylalanine
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
53
PharmaCompass offers a list of Bosentan Hydrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Bosentan Hydrate manufacturer or Bosentan Hydrate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Bosentan Hydrate manufacturer or Bosentan Hydrate supplier.
PharmaCompass also assists you with knowing the Bosentan Hydrate API Price utilized in the formulation of products. Bosentan Hydrate API Price is not always fixed or binding as the Bosentan Hydrate Price is obtained through a variety of data sources. The Bosentan Hydrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Actelion brand of bosentan monohydrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Actelion brand of bosentan monohydrate, including repackagers and relabelers. The FDA regulates Actelion brand of bosentan monohydrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Actelion brand of bosentan monohydrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Actelion brand of bosentan monohydrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Actelion brand of bosentan monohydrate supplier is an individual or a company that provides Actelion brand of bosentan monohydrate active pharmaceutical ingredient (API) or Actelion brand of bosentan monohydrate finished formulations upon request. The Actelion brand of bosentan monohydrate suppliers may include Actelion brand of bosentan monohydrate API manufacturers, exporters, distributors and traders.
click here to find a list of Actelion brand of bosentan monohydrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Actelion brand of bosentan monohydrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Actelion brand of bosentan monohydrate active pharmaceutical ingredient (API) in detail. Different forms of Actelion brand of bosentan monohydrate DMFs exist exist since differing nations have different regulations, such as Actelion brand of bosentan monohydrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Actelion brand of bosentan monohydrate DMF submitted to regulatory agencies in the US is known as a USDMF. Actelion brand of bosentan monohydrate USDMF includes data on Actelion brand of bosentan monohydrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Actelion brand of bosentan monohydrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Actelion brand of bosentan monohydrate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Actelion brand of bosentan monohydrate Drug Master File in Japan (Actelion brand of bosentan monohydrate JDMF) empowers Actelion brand of bosentan monohydrate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Actelion brand of bosentan monohydrate JDMF during the approval evaluation for pharmaceutical products. At the time of Actelion brand of bosentan monohydrate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Actelion brand of bosentan monohydrate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Actelion brand of bosentan monohydrate Drug Master File in Korea (Actelion brand of bosentan monohydrate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Actelion brand of bosentan monohydrate. The MFDS reviews the Actelion brand of bosentan monohydrate KDMF as part of the drug registration process and uses the information provided in the Actelion brand of bosentan monohydrate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Actelion brand of bosentan monohydrate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Actelion brand of bosentan monohydrate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Actelion brand of bosentan monohydrate suppliers with KDMF on PharmaCompass.
A Actelion brand of bosentan monohydrate written confirmation (Actelion brand of bosentan monohydrate WC) is an official document issued by a regulatory agency to a Actelion brand of bosentan monohydrate manufacturer, verifying that the manufacturing facility of a Actelion brand of bosentan monohydrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Actelion brand of bosentan monohydrate APIs or Actelion brand of bosentan monohydrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Actelion brand of bosentan monohydrate WC (written confirmation) as part of the regulatory process.
click here to find a list of Actelion brand of bosentan monohydrate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Actelion brand of bosentan monohydrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Actelion brand of bosentan monohydrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Actelion brand of bosentan monohydrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Actelion brand of bosentan monohydrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Actelion brand of bosentan monohydrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Actelion brand of bosentan monohydrate suppliers with NDC on PharmaCompass.
Actelion brand of bosentan monohydrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Actelion brand of bosentan monohydrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Actelion brand of bosentan monohydrate GMP manufacturer or Actelion brand of bosentan monohydrate GMP API supplier for your needs.
A Actelion brand of bosentan monohydrate CoA (Certificate of Analysis) is a formal document that attests to Actelion brand of bosentan monohydrate's compliance with Actelion brand of bosentan monohydrate specifications and serves as a tool for batch-level quality control.
Actelion brand of bosentan monohydrate CoA mostly includes findings from lab analyses of a specific batch. For each Actelion brand of bosentan monohydrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Actelion brand of bosentan monohydrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Actelion brand of bosentan monohydrate EP), Actelion brand of bosentan monohydrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Actelion brand of bosentan monohydrate USP).